Gilead Sciences (GILD) Total Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Current Liabilities for 18 consecutive years, with $11.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 1.51% year-over-year to $11.0 billion; the trailing twelve-month figure through Jun 2026 stood at $11.0 billion (down 1.51% YoY), and the FY2025 full-year result was $11.8 billion, down 1.59% from the prior year.
• Total Current Liabilities advanced to $11.0 billion in Q2 2026 per GILD's latest filing, from $9.5 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.0 billion in Q2 2023 and bottomed at $8.6 billion in Q1 2022.
• Historically, Total Current Liabilities has averaged $11.3 billion across 5 years, with a median of $11.3 billion in 2022.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities surged 51.45% in 2023, then retreated 23.23% in 2026.
• Over 5 years, Total Current Liabilities stood at $11.2 billion in 2022, then grew by 0.38% to $11.3 billion in 2023, then grew by 6.42% to $12.0 billion in 2024, then decreased by 1.59% to $11.8 billion in 2025, then dropped by 6.71% to $11.0 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $11.0 billion, $9.5 billion, and $11.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.